Utility of tissue elafin as an immunohistochemical marker for diagnosis of acute skin graft-versus-host disease: a pilot study

Mahabal, G.; George, Leni; Peter, Dincy; Bindra, Mandeep Singh; Thomas, Maya; Srivastava, Alok; George, Biju; Pulimood, Susanne

doi:10.1111/ced.13678

Cited by 17 publications

(17 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They also demonstrated that elafin-high aGVHD lesions presented with epidermal thickening and were associated with poor clinical outcomes [12]. More recently, Mahabal GD et al indicated that tissue elafin is a useful immunohistochemical marker for skin aGVHD, and the sensitivity and specificity of elafin immunohistochemistry to predict acute skin GVHD were 100 and 75%, respectively [67]. Although the biomarker of skin aGVHD, elafin, is more specific, most skin aGVHD is easy to control, and the incidence of associated mortality is very low.…”

Section: Exploratory Studies Of Agvhd Biomarkersmentioning

confidence: 99%

Seeking biomarkers for acute graft-versus-host disease: where we are and where we are heading?

Zhao

Huang

2019

Biomark Res

View full text Add to dashboard Cite

Acute graft-versus-host disease (aGVHD) is one of the most important complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT), which would seriously affect the clinical outcomes of patients. Early diagnosis and early intervention are keys for improving its curative efficacy. Thus, seeking the biomarkers of aGVHD that can accurately identify and diagnose aGVHD is very important to guiding the intervention and treatment of aGVHD. For the past decades, many studies have focused on searching for aGVHD-related biological markers to assist in diagnosis, early warning, and risk stratification. Unfortunately, until now, no reliable aGVHD biomarker is available that is recognized and widely used in clinical practice. With the continuous development of biological technology, as well as our in-depth understanding of the pathophysiologic mechanism of aGVHD, the selection, examination and application of biological markers have changed much. In this review, we summarized the progress of aGVHD biological marker screening, identification, preliminary clinical application, and look forward to a promising development direction in the future.

show abstract

Section: Exploratory Studies Of Agvhd Biomarkersmentioning

confidence: 99%

Seeking biomarkers for acute graft-versus-host disease: where we are and where we are heading?

Zhao

Huang

2019

Biomark Res

View full text Add to dashboard Cite

show abstract

“…Several authors have attempted to identify histopathological and IHC markers that allow the distinction of aGVHD from SDRs . In the present study, vacuolar interface changes were observed in all aGVHD and all SDRs cases.…”

Section: Discussionmentioning

confidence: 50%

“…In our study, we found infiltrates by CD4+ and CD8+ T lymphocytes in both aGVDH and SDRs, with no significant differences between them. The increased expression of elafin, intercellular adhesion molecule‐I (ICAM‐1), and HLA‐DR antigens in keratinocytes have further been reported in aGVHD skin biopsies …”

Section: Discussionmentioning

confidence: 82%

Are apoptosis‐determining techniques useful to establish an early diagnosis of acute graft‐vs‐host disease in pediatric patients under treatment with multiple drugs?

et al. 2020

View full text Add to dashboard Cite

Background: There are no pathognomonic histopathological features to distinguish acute graft-vs-host disease (aGVHD) from skin drug reactions (SDRs) in pediatric patients with multiple drug regimens that have received blood transfusions and/or transplants. We aimed to determine if the addition of apoptosis markers is helpful to distinguish aGVHD from SDRs in these patients. Methods: Skin biopsy specimens from patients with a clinical diagnosis of aGVHD orSDRs were evaluated for the presence of apoptotic bodies, satellitosis, interface damage, vasculitis, and inflammatory infiltrate on H&E stain. Information was completed with apoptotic markers (transferase-mediated dUTP nick end-labeling[TUNEL], bcl-2, and caspase-3). Results:The skin biopsy specimens of 32 patients with aGVHD and 11 with SDRs were included for study. Only the number of apoptotic keratinocytes per 10 high-power fields (hpf) showed a significant difference between both groups (P = 0.02); the presence of ≥4 apoptotic keratinocytes per 10 hpf was identified as the optimal cut-off point to discriminate aGVHD from SDRs. No SDRs cases had follicular apoptotic cells. TUNEL, bcl-2, and caspase-3 determination showed no difference between both groups. Conclusions:The presence of ≥4 apoptotic keratinocytes per 10 hpf (in aGVHD) and the absence of follicular apoptotic cells (in SDRs) might be a useful marker to distinguish between them.

show abstract

“…[24] Skin biomarkers Elafin Diagnostic Elafin expression in the skin was associated with cutaneous aGVHD diagnosis. [38] Skin and intestinal biomarkers…”

Section: Reg3amentioning

confidence: 99%

MicroRNAs as Potential Diagnostic, Prognostic, and Predictive Biomarkers for Acute Graft-versus-Host Disease

Motaei

Yaghmaie

Ahmadvand

et al. 2019

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

Successful treatment of various hematologic diseases with allogeneic hematopoietic stem cell transplantation is often limited due to the occurrence of acute graft-versus-host disease (aGVHD). So far, there are no approved molecular biomarkers for the diagnosis and prediction of aGVHD at the clinical level due to our incomplete understanding of the molecular biology of the disease. Various studies have been conducted on animal models and humans to investigate the role of microRNAs in aGVHD pathogenesis to implicate them as biomarkers and therapeutic targets. Because of their high stability, tissue specificity, ease of measurement, low cost, and simplicity, they are excellent targets for biomarkers. In this review, we focused on microRNA expression profiling studies that were performed recently in both animal models and human cases of aGVHD to identify diagnostic and predictive biomarkers for this disease. The expression pattern of microRNAs can be specific to cells and tissues. Because aGVHD affects several organs, microRNA signatures in target tissues may help to understand the molecular pathology of the disease. Identification of organ-specific microRNAs in aGVHD can be promising to categorize patients for organ-specific therapies. Thus, microRNAs can be used as noninvasive diagnostic tests in clinic to improve prophylaxis, predict incidence and severity, and reduce morbidity.

show abstract

Utility of tissue elafin as an immunohistochemical marker for diagnosis of acute skin graft-versus-host disease: a pilot study

Abstract: Tissue elafin is a useful immunohistochemical marker for acute skin GvHD. However, larger studies are needed to validate these results.

Cited by 17 publications

References 24 publications

Seeking biomarkers for acute graft-versus-host disease: where we are and where we are heading?

Seeking biomarkers for acute graft-versus-host disease: where we are and where we are heading?

Are apoptosis‐determining techniques useful to establish an early diagnosis of acute graft‐vs‐host disease in pediatric patients under treatment with multiple drugs?

MicroRNAs as Potential Diagnostic, Prognostic, and Predictive Biomarkers for Acute Graft-versus-Host Disease

Contact Info

Product

Resources

About